Ivermectin is one of the most consequential drugs to come out of soil science, a genuine triumph of twentieth-century parasitology that still saves sight and limbs in the developing world today. This article explains, in plain terms, how ivermectin actually works at the molecular level, what that mechanism does and does not tell us about its uses, and what the best available clinical evidence shows — including for questions, like COVID-19, where the honest answer is less exciting than the rumor.

What Ivermectin Is and Where It Came From

Ivermectin is a semi-synthetic derivative of avermectin, a family of compounds first isolated in the late 1970s from Streptomyces avermitilis, a bacterium found in a soil sample collected near a golf course in Japan. The Japanese microbiologist Satoshi Ōmura isolated the organism, and the Irish-American parasitologist William Campbell, working at Merck, showed that its derivatives were extraordinarily effective against parasitic worms in animals. Their work was recognized with a share of the 2015 Nobel Prize in Physiology or Medicine, awarded specifically for discoveries that transformed the treatment of parasitic disease. It is worth pausing on that origin: a molecule capable of relieving one of the great causes of preventable blindness in human history was sitting quietly in ordinary dirt, waiting to be found. Whatever one's view of how such order came to be woven into creation, it is a humbling reminder that the natural world has depths still worth careful, patient study.

Ivermectin tablets are sold under various generic labels and, in the United States, under the FDA-approved brand name Stromectol, as well as in generic form. It also exists as a topical cream and lotion for skin conditions. The oral tablets are manufactured in a few standard strengths — commonly 3 mg and 6 mg in the United States, with 12 mg tablets also produced and used in some other countries — and the dose a patient needs is calculated by body weight, not simply by picking a tablet size off a shelf.

The Molecular Mechanism: Chloride Channels That Only Parasites Have

Ivermectin's central mechanism is well characterized in pharmacology: it binds with high affinity to glutamate-gated chloride channels, a type of ion channel found in the nerve and muscle cells of nematodes (roundworms), insects, and other invertebrates. When ivermectin locks onto these channels, it holds them open. Chloride ions flood into the cell, the cell membrane becomes hyperpolarized, and the nerve or muscle cell can no longer fire normally. The practical result in the parasite is flaccid paralysis: the worm or mite can no longer feed, move, or reproduce, and it is cleared or dies. At higher concentrations, ivermectin also enhances the activity of GABA-gated chloride channels, a second, related route to the same paralytic effect. This dual action on chloride channel physiology is why ivermectin is so reliably effective against a wide range of nematodes and arthropods, from the filarial worms that cause river blindness to the mites that cause scabies.

This is not a hypothesis drawn from folklore or anecdote. The glutamate-gated chloride channel mechanism was worked out through decades of pharmacological and electrophysiological research, including studies on the nematode Caenorhabditis elegans, and it remains the textbook explanation cited in standard pharmacology references. It is one of the cleaner, better-understood mechanisms of action in all of antiparasitic medicine.

Why the Same Dose Doesn't Paralyze the Patient

The reason ivermectin is safe for humans and animals at approved doses, while devastating to parasites, comes down to two facts of mammalian biology. First, vertebrates — including humans — do not have glutamate-gated chloride channels; our nervous systems use different receptor architecture entirely, so ivermectin has no equivalent target to lock onto in human nerve tissue. Second, even the GABA-gated channels that mammals do possess are tucked safely behind the blood-brain barrier, and ivermectin is actively pumped back out of the central nervous system by a transporter protein called P-glycoprotein. This is the same reason certain dog breeds with a genetic mutation in that transporter (notably some collies) can suffer severe ivermectin toxicity at doses that are harmless to humans and most other animals — their pump doesn't work properly, and the drug reaches their brain. In people with normal P-glycoprotein function, this efflux mechanism keeps ivermectin's exposure to the central nervous system very low, which is the pharmacological basis of its wide margin of safety at approved doses.

Approved Uses: What Ivermectin Tablets Are Actually For

In humans, oral ivermectin is approved by the FDA for two parasitic infections:

Topical ivermectin cream is approved for rosacea, and a topical lotion is approved for head lice. Ivermectin is also used off-label, based on substantial clinical experience and guideline support, for scabies and for lymphatic filariasis as part of international mass treatment campaigns. Dosing is calculated by body weight — commonly around 200 micrograms per kilogram for a single dose in onchocerciasis and strongyloidiasis regimens — which is why tablets come in different strengths and why a physician, not a dosage chart found online, should determine how many milligrams a given patient needs. Ivermectin is not approved, and should not be assumed suitable, for use in young children under roughly 15 kilograms of body weight, and it is not recommended during pregnancy except when a physician judges the benefit clearly outweighs the risk.

Ivermectin and COVID-19: What the Trials Actually Found

Ivermectin drew enormous public attention during the COVID-19 pandemic after early laboratory work — notably an in vitro study from Monash University in Australia, published in 2020 — showed that ivermectin could reduce viral RNA in cell culture. That finding was real, but it came with an important caveat that was often lost in public discussion: the concentrations needed to produce that effect in a laboratory dish were far higher than what can be safely achieved in human blood or lung tissue at approved doses. A promising signal in a petri dish does not automatically translate into a benefit in a sick patient, and here it did not.

Since then, ivermectin has been tested for COVID-19 in several large, well-designed randomized controlled trials. The TOGETHER trial, a multi-country platform trial coordinated through McMaster University and Brazilian research centers and published in the New England Journal of Medicine in 2022, found no significant reduction in hospitalization among COVID-19 patients treated with ivermectin compared with placebo. The ACTIV-6 trial, funded by the U.S. National Institutes of Health and published in JAMA in 2022, similarly found that ivermectin did not meaningfully shorten symptom recovery time in outpatients with mild-to-moderate COVID-19. A Cochrane systematic review, updated in 2021 and again afterward, evaluated the pooled trial evidence and concluded there was no reliable evidence that ivermectin prevents or effectively treats COVID-19, rating the certainty of existing evidence as low. Some of the earlier, more optimistic studies that fueled public interest were later found to have serious data problems; one widely cited preprint from Egypt was withdrawn from the platform hosting it after independent researchers flagged irregularities in its dataset, a normal and healthy part of scientific self-correction rather than evidence of any coordinated effort to mislead.

The honest summary is this: ivermectin is not FDA-approved for the prevention or treatment of COVID-19, and the largest, most rigorous trials conducted to date have not shown a clinically meaningful benefit for that purpose. That does not diminish what ivermectin genuinely accomplishes against the parasites it was designed for. It simply means good stewardship of one's health means following the evidence where it actually leads, not where early hope pointed.

Safety and Using Ivermectin Responsibly

At approved human doses, ivermectin is generally well tolerated. Reported side effects are usually mild — dizziness, nausea, and itching — though patients being treated for onchocerciasis can experience a more pronounced reaction called the Mazzotti reaction, caused by the immune response to dying worms rather than the drug itself, and this needs medical supervision. A critical safety point, and one worth stating plainly for any reader considering self-treatment: veterinary ivermectin formulations, made for livestock, are far more concentrated and are not formulated, dosed, or purified to the standard required for human use. The FDA has specifically warned against people taking animal ivermectin products, and this is not a matter of institutional overcaution — the concentrations involved genuinely differ by orders of magnitude, and dosing errors have sent people to emergency departments.

None of this is an argument against thinking for yourself or asking hard questions of your physician — quite the opposite. A patient who understands why a drug works, and what has and has not been shown about its uses, is better equipped to have an honest conversation with their own doctor and to make an informed decision about their own care. That is exactly how medical freedom is meant to function: not by skipping the physician, but by walking into that appointment as an informed partner rather than a passive recipient of instructions.

Key takeaway: Ivermectin reliably paralyzes and kills parasites by acting on chloride channels that human nerve cells simply do not have, which explains its genuine, well-established value against worms and mites — but that same mechanism gives no reason to expect it to work against a virus, and the largest human trials to date confirm it does not meaningfully help against COVID-19.